Gemogenovatucel-T

N/A

Report date: 2025/02/07 10:23:32
First In Class

Base Information

Drug NameGemogenovatucel-T
Drug Alias NameBi-shRNAfurin自体肿瘤细胞产物 - Gradalis/Mary Crowley自体肿瘤细胞产品 - Gradalis/Mary CrowleyTGFbeta2 antisense + rhGMCSF vaccineVigil EATC +[12] 
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionFurin inhibitorsMacrophage colony stimulating factor 2 Gene transference
TargetsFurinMacrophage colony stimulating factor 2
Therapy Area/IndicationsUterine Cervical NeoplasmsEndometrial NeoplasmsUterine Neoplasms +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesGradalis Inc
China Registration ClassN/A

Develop Information

Active CompaniesMary Crowley Cancer Research CenterGradalis Inc
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsUterine NeoplasmsOvarian Neoplasms +[5] 
Inactive IndicationsEndometrial NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 

Other Information

ATC CodeN/A
Related LinksN/A